Replication-competent oncolytic herpes simplex viruses (HSV), modified by deletion of certain viral growth genes, can selectively target malignant cells. The viral growth gene g 1 34.5 has significant homology to GADD34 (growth arrest and DNA damage protein 34), which promotes cell cycle arrest and DNA repair in response to stressors such as radiation (XRT). By upregulating GADD34, XRT may result in greater oncolytic activity of HSV strains deficient in the g 1 34.5 gene. The human cholangiocarcinoma cell lines KMBC, SK-ChA-1 and YoMi were treated with NV1023, an oncolytic HSV lacking one copy of g 1 34.5. Viral proliferation assays were performed at a multiplicity of infection (MOI, number of viral particles per tumor cell) equal to 1, either alone or after XRT at 250 or 500 cGy. Viral replication was assessed by plaque assay. In vitro cytotoxicity assays were performed using virus at MOIs of 0.01 and 0.1, with or without XRT at 250 cGy and cell survival determined with lactate dehydrogenase assay. Established flank tumors in athymic mice were treated with a single intratumoral injection of virus (10 3 or 10 4 plaque forming units), either alone or after a single dose of XRT at 500 cGy, and tumor volumes measured. RT-PCR was used to measure GADD34 mRNA levels in all cell lines after a single dose of XRT at 250 or 500 cGy. NV1023 was tumoricidal in all three cell lines, but sensitivity to the virus varied.
Introduction
Cholangiocarcinoma is a lethal disease, for which there are few effective treatments. Complete resection remains the only potentially curative therapy but is possible in the minority of patients.
1,2 Standard chemotherapeutic agents alone are largely ineffective. Radiation therapy is often used in patients with locally advanced disease and may offer some benefit but can be associated with significant toxicity. [3] [4] [5] Clearly, for the majority of patients with unresectable tumors, more effective treatment strategies are necessary if morbidity and mortality related to cholangiocarcinoma are to be reduced.
Replication-competent oncolytic herpes simplex viruses (HSV) are novel tumoricidal agents with potent activity against a wide range of human cancer cell lines. [6] [7] [8] Oncolytic HSV are replication competent but modified by deletion of certain strategic viral growth genes, the protein products of which are expressed at higher levels in tumor cells compared to normal cells. As a result, tumor cells, unlike normal cells, support viral replication and are specifically targeted for viral-induced cell lysis. An attractive feature of replication-competent HSV is that a large number of progeny virus arise from relatively few initially infected cells so that injection of a large viral load can be avoided.
Recent studies have suggested a synergistic antitumor effect of HSV when combined with ionizing radiation (XRT). [9] [10] [11] The molecular mechanism underlying this interaction is unclear but may be related to radiationinduced upregulation of certain gene products whose function or functions are similar to deleted viral gene products, thereby promoting viral replication. One such potential protein is GADD34, which is upregulated under conditions of DNA damage and cellular injury (such as XRT) and shares significant homology with the HSV protein ICP45 encoded by the g 1 34.5 gene.
12-14 g 1 34.5 is associated with neurovirulence and its absence results in attenuated viral activity. 15 Upregulation of GADD34 with XRT may therefore complement the deletion of g 1 34.5 in the viral genome by enhancing viral antitumor activity but potentially limiting viral cytotoxicity to the radiation field.
The current study evaluates the efficacy of oncolytic HSV (NV1023) combined with XRT in human cholangiocarcinoma cell lines. Such an approach is attractive since it may result in more effective tumor control using lower doses of both individual agents, thereby reducing toxicity. This strategy would be useful not only in cholangiocarcinoma but also in other malignancies commonly treated with XRT, such as pancreatic, rectal, prostate and head/neck cancer.
Materials and methods

Cells
Three human cholangiocarcinoma cell lines were used in all experiments: KMBC (Japan Health Services, Osaka, Japan);
16 SK-ChA-1 (a gift from Dr A Knuth, Frankfurt, Germany); 17 YoMi (RIKEN Cell Bank, Ibaraki, Japan, with permission of Dr Takeshi Todoroki). KMBC, SK-ChA-1 and YoMi are derived from extrahepatic bile duct cancers. KMBC cells were maintained in Dulbecco's modified Eagle's medium (DMEM) high glucose to F-12 1:1 ratio supplemented with 5% fetal calf serum, 2 mM L-glutamine, 100 mg/ml penicillin and 100 mg/ml streptomycin. SK-ChA-1 cells were cultured in DMEM high glucose with 10% fetal calf serum, 100 mg/ml penicillin and 100 mg/ml streptomycin. YoMi cells were maintained in DME supplemented with 10% fetal calf serum, 100 mg/ ml penicillin and 100 mg/ml streptomycin. Vero cells (African green monkey kidney cells (ATCC), used for viral titering assays) were grown in minimal essential medium with 10% fetal calf serum, 100 mg/ml penicillin and 100 mg/ml streptomycin. Viruses NV1023, a replication-competent HSV (Medigene, San Diego, CA), was used for all in vitro and in vivo studies. NV1023 was derived from NV1020, itself clonally derived from R7020, [18] [19] [20] by insertion of a 5.2 kb fragment of HSV-2 DNA containing the genes US2-2 to US2-5 into the U L/S junction. NV1023 also differs from NV1020 in that NV1023 has a replacement of the endogenous thymidine kinase gene and the adjoining U L 24 promoter region has been repaired. In addition, the Escherichia coli lacZ marker gene has been inserted into the ICP47 locus, which deletes US11 and 50% of US10. NV1023 has been attenuated by a deletion extending from the 3 0 end of UL55 to the ICP4 promoter, which deletes UL56 and one copy each of the diploid genes ICP0, ICP4 and g 1 34.5. The synthesis of this virus has previously been described. 21, 22 NV1023 was propagated on Vero cells and titered using standard plaque assays.
In vitro viral proliferation Viral proliferation curves were generated to demonstrate viral replication in all cholangiocarcinoma cell lines. KMBC (5 Â 10 were grown in 12-well plates (BD Biosciences, Bedford, MA) and infected with NV1023 at a multiplicity of infection (MOI, ratio of viral particles to target cells) of 1.0 (1 Â 10 4 or 2 Â 10 4 plaque forming units (PFU)). Different initial cell concentrations were used because of differences in cell proliferation rates. Cells and supernatants were harvested daily for 6 days after infection. Cells were lysed by three freeze-thaw cycles and viral titers were determined by standard plaque assay using Vero cells. All assays were performed in triplicate.
Viral proliferation assays were repeated in all cell lines to assess the impact of external beam radiation (XRT) on viral replication. KMBC (5 Â 10 . After 24 h, NV1023 was added to the cells at an MOI of 1.0; cells and supernatants were collected at 12 h and then daily for 6 days after infection. After cell lysis, viral titers were determined by standard plaque assay using Vero cells. All infections were performed in triplicate.
In vitro cytotoxicity
In vitro cytotoxicity assays were used to assess the tumoricidal efficacy of NV1023 and XRT, both alone and in combination, for all cell lines. These assays were performed using NV1023 at MOIs of 0.1 and 0.01 and a single XRT dose of 250 cGy. These doses were determined from preliminary studies showing that higher viral and radiation doses resulted in excessive tumor cell killing at 7 days, which precluded meaningful comparisons among treatment groups and did not allow an assessment of the impact of combined therapy. Cell viability was assessed using lactate dehydrogenase (LDH) release assays (CytoTox 96, Promega, Madison, WI). Cytotoxicity data are presented as the percentage of LDH release from viable cells compared to that in untreated controls. All assays were performed in triplicate.
NV1023 alone: At 12 h after plating (as above), cells were infected with NV1023 at MOIs of 0.01 or 0.1. On days 1, 3, 5 and 7 after infection, cells were lysed with 1.5% Triton-X in phosphate-buffered solution (PBS) and the lysate was analyzed for LDH concentration using the CytoTox 96 Kit according to the manufacturer's specifications. Absorbance at 450 nm was measured on a microplate reader (EL 312e, Bio-Tek Instruments, Winooski, VT). XRT alone: At 12 h after plating, cells were treated with 250 cGy, and cytotoxicity assays performed on days 1, 3, 5 and 7 after irradiation, as described above. NV1023 and XRT in combination: Cells were irradiated (250 cGy) 12 h after plating. NV1023 was added to the cells immediately after irradiation at MOIs of 0.01 or 0.1. Cells were harvested for cytotoxicity assays as above. The treatment groups comprising the in vitro cytotoxicity studies were therefore as follows: (1) XRT alone at 250 cGy; (2) NV1023 alone at an MOI of 0.01; (3) NV1023 alone at an MOI of 0.1; (4) XRT at 250 cGy plus NV1023 at an MOI of 0.01; and (5) XRT at 250 cGy plus NV1023 at an MOI of 0.1.
Establishment of flank tumors in nude mice
Male athymic mice were purchased from the National Cancer Institute (Bethesda, MD), housed five per cage and provided food and water ad libitum. Animals were anesthetized using ketamine and xylazine, administered by intraperitoneal injection (70 mg/kg ketamine/10 mg/kg xylazine). Tumors were generated by subcutaneous flank injection of 1 Â 10 6 -10 7 cells in 50 ml of PBS. The mice were returned to their cages and followed daily until tumors measuring approximately 5 mm in greatest diameter were detected.
Treatment of flank tumors with NV1023 and XRT
Once the tumors reached an appropriate size for treatment, animals were randomized into six treatment groups with 5-8 animals each; animals with no evidence of growing tumors were excluded. The treatment groups were as follows: (1) control; (2) 500 cGy XRT alone; (3) a single intratumoral injection of NV1023 alone (1 Â 103 PFU); (4) a single intratumoral injection of NV1023 alone (1 Â 10 4 PFU); (5) 500 cGy XRT followed by a single intratumoral injection of 1 Â 10 3 PFU NV1023; and (6) 500 cGy XRT followed by a single intratumoral injection of 1 Â 10 4 PFU NV1023. In the NV1023/XRT combination treatment groups, virus was injected 24 h after irradiation; control and XRT alone groups were given an intratumoral injection of PBS at the same time. Animals in the radiation groups were shielded with lead during tumor treatment with XRT. The radiation and viral dosages used were determined from preliminary studies to be optimal for assessing differences between each treatment.
Flank tumor volumes were measured with calipers every 3-4 days for 3 weeks. Tumor volume was calculated using the formula for an ellipsoid volume ¼ (4/ 3)(p)(length/2)(width/2) 2 . Animal weights, grooming habits, and food and water intake were assessed three times per week in order to assess for toxicity from the treatment or pain related to the tumor. It is the authors' policy to sacrifice any animal showing signs of distress or if the greatest tumor dimension exceeded 2 cm or if there was evidence of skin ulceration. No animal in any treatment group required sacrifice during the 3-week tumor measurement portion of the study.
Real-Time RT-PCR analysis for GADD34 in irradiated cholangiocarcinoma cells
Cells from each line were grown to 80% confluence in T-225 cell culture flasks and treated with 250 or 500 cGy XRT. Cells were trypsinized and pelleted for RNA isolation at various time points after irradiation. The cell pellets were lysed using Qiagen QIAshredder and RNA was purified by the Qiagen RNeasy Kit. cDNA was produced from each RNA sample using the Bio-Rad iScript cDNA Synthesis Kit. The GADD34 and 18-S cDNA was analyzed using Bio-Rad iQ SYBR Green Supermix on the Bio-Rad ICycler. For GADD-34 and 18-S, the following primers were used, respectively: 5 0 -GGA HHA AGA GAA TCA AGC CA-3 0 (forward) and 5 0 -TGG GGT CGG AGC CTG AAG AT-3 0 (reverse); 5 0 -GTA ACC CGT TGA ACC CCA TT-3 0 (forward) and 5 0 -CCA TCC AAT CGG TAG TAG CG-3 0 (reverse). The amount of GADD34 RNA in each sample was normalized to the concentration of 18S RNA. GADD 34 RNA expression in nonirradiated cells from each line served as the baseline expression for the 12 and 24 h time points.
Statistics
Results are expressed as the mean7standard error of the mean, unless otherwise indicated. Continuous variables were compared using the Student's t-test. Flank tumor volumes 3 weeks after the start of treatment were used for comparisons among the different groups. The possibility of a synergistic relationship between NV1023 and XRT was explored by first calculating the percentage change in tumor volume from baseline for each treatment group. Under an additive model, the percent change for the combination treatment groups should be approximately equal to the sum of the percentage change in each single therapy arm. The difference between the percentage change in the combination therapy groups and the sum of the percentage changes of each single therapy group was calculated, with a positive value suggesting synergy and a negative value suggesting antagonism. An interaction term was used in an analysis of variance model to test the null hypothesis that the models were additive.
Results
In vitro viral proliferation These assays showed that NV1023 is capable of infecting and replicating in all four cholangiocarcinoma cell lines at an MOI of 1.0 (Figure 1 Pretreatment with XRT at 250 or 500 cGy substantially increased the peak in viral proliferation (Figure 2) , with some variation among the different cell lines. KMBC cells exhibited a similar increase at both radiation doses (Po0.85). By contrast, the viral burst was higher at 250 cGy than at 500 cGy in SK-ChA-1 cells (Po0.11). The opposite was true of YoMi cells, which showed a modest increase at 250 cGy but a much greater increase at 500 cGy (Po0.007). These differences may, in part, reflect differences in radiation sensitivity among the different cell lines (see below).
In vitro cytotoxicity
At an MOI of 1.0, NV1023 resulted in 450% cell death in all cell lines by day 7 ( Figure 3A ). NV1023 at this dose was particularly effective in YoMi (1.6% of control at day 7) and KMBC (21.6% of control at day 7) cells. Because of the efficacy of the virus in killing tumor cells at this dose, subsequent studies were performed using MOIs of 0.01 and 0.1 and a single XRT dose of 250 cGy in order to better evaluate the impact of combined viral and radiation therapy ( Figure 3B ). NV1023, at these lower MOIs, had a much more modest cytotoxic effect at 7 days in KMBC and SK-ChA-1 cells. By contrast, YoMi cells remained sensitive to the virus, even at an MOI of 0.01. The variable sensitivity to low-dose XRT was also evident in these assays. SK-ChA-1 cells were the most sensitive to XRT, while XRT had a more modest impact on KMBC cells and was only minimally effective in YoMi cells.
In KMBC cells, combination treatment with NV1023 at an MOI of 0.1 and XRT resulted in the greatest tumor cell killing at day 7. On the other hand, combination treatment with NV1023 at an MOI of 0.01 was little different than XRT alone. SK-ChA-1 cells were particularly sensitive to XRT, and the addition of virus did not appear to result in greater cytotoxicity. In YoMi cells, because of their exquisite sensitivity to NV1023, evidence of increased efficacy with combination treatment was seen only at the lower viral dose.
In vivo cytotoxicity: treatment of flank tumors in nude mice Flank tumors derived from each cell line were established as above and then subjected to XRT alone at 500 cGy, NV1023 alone (10 3 or 10 4 PFU) or combination treatment with XRT at 500 cGy plus NV1023 at either 10 3 or 10 4 PFU. The number of animals for each tumor cell line was as follows: KMBC (43), SK-ChA-1 (40) and YoMi (42). The data are illustrated in Figure 4 ; Figure 4a shows results using 10 3 PFU NV1023 (both alone and in combination with XRT), while Figure 4b shows the results with 10 4 PFU. The control and XRT alone groups are the same in both and are included for comparison purposes. The combination treatment data are presented separately for clarity.
The in vivo results generally mirrored the in vitro data, in that SK-ChA-1 tumors showed greater sensitivity to XRT than to NV1023, while the converse was true of YoMi tumors, and the tumoricidal effect of each individual treatment appeared to be similar in KMBC tumors. Combination treatment with virus and XRT resulted in the greatest tumor volume reduction in all four (Figure 4b ). Combination therapy with this viral dose decreased tumor volume by 89.9% compared to virus alone (Po0.077), by 81.4% compared to XRT alone (Po0.076) and by 76.1% compared to A synergistic tumoricidal effect of virus and XRT was suggested in YoMi tumors, where the results of combined therapy seemed to be greater than the sum of the individual treatments. At a viral dose of 10 3 PFU, the percentage tumor volume reduction (from baseline) in the combination therapy group was 46% higher than a simple additive model would have predicted, and was 28% higher than predicted at a viral dose of 10 4 PFU. By contrast, there was no suggestion of synergistic activity in KMBC or SK-ChA-1 tumors. Combination treatment of KMBC tumors using virus at 10 3 and 10 4 PFU resulted in 138 and 147% less tumor volume reduction, respectively, than an additive model would have predicted; the results with SK-ChA-1 tumors were 48 and 35% less than predicted. None of these differences achieved statistical significance, however, likely the result of small sample size.
Real-Time RT-PCR analysis for GADD34 in irradiated cholangiocarcinoma cells
After irradiation with 250 and 500 cGy, marked increase in expression of GADD34 mRNA was seen only in YoMi cells ( Figure 5 ). Increased GADD34 expression was noted at 12 h at both radiation doses but was more sustained at 500 cGy; none of the other cell lines showed any increase in GADD35 mRNA levels above baseline.
Discussion
Cholangiocarcinoma is an uncommon malignancy with an overall poor prognosis. Untreated, patients will usually die within 12 months from the time of diagnosis. Complete resection remains the most effective and only potentially curative therapy, with 5-year survival rates of 30-40%. 1, 2 Even with an R0 resection, however, the Treatment of cholangiocarcinoma WR Jarnagin et al majority of patients develop recurrent disease, commonly at local/regional sites. 23 Unfortunately, limited treatment options exist for the large proportion of patients with unresectable disease at presentation or with recurrent disease after resection. Chemoradiation therapy is often used for unresectable, locally advanced tumors or for local/regional recurrences, and may provide some measure of disease control, although a clear survival benefit has not been demonstrated. [3] [4] [5] A major limitation of such treatment, particularly radiation therapy, is toxicity. If mortality related to cholangiocarcinoma is to be reduced beyond its current high level, more effective therapies must be developed.
Genetically modified oncolytic HSV are novel antineoplastic agents with potent activity against a wide array of tumors, including human cell lines in nude mouse models and animal tumors derived from syngeneic animal cell lines. [6] [7] [8] The ability to manipulate the viral genome has resulted in the generation of viral strains that specifically target malignant cells for viral-induced lysis, with attenuated toxicity to normal tissues. In particular, the deletion of certain key viral growth genes, the protein products of which are either inducible or expressed at high baseline levels in cancer cells, is an attractive means of selectively promoting viral proliferation. The virus used in the present study, NV1023, is an example of such a viral strain. Deletion of one copy of the g 1 34.5 gene, in addition to other modifications, serves to attenuate NV1023's virulence. Interestingly, the protein product of g 1 34.5 (ICP45) shares significant homology with the cellular protein GADD34. Several studies have shown increased viral tumoricidal activity when combined with XRT, [9] [10] [11] and it has been suggested that XRT-induced upregulation of GADD34 may mediate this synergistic effect. 24 The results of the present study appear to support a role for GADD34 in enhancing oncolytic HSV tumoricidal activity after XRT, but further suggest that this is cell type specific. The concept of cell type specificity to enhanced viral replication was suggested by Chung et al., 10 who observed differential effects of combined oncolytic viral and XRT in hepatoma cell lines. In the present study, in vitro viral proliferation was increased after XRT in all three cell lines, regardless of GADD34 status, although a dose-dependent response was seen only in YoMi cells. The flank xenograft experiments showed that, despite variable sensitivity to NV1023 and XRT, low-dose combination therapy was effective in all cell lines; however, the greatest volume reduction was seen in tumors derived from YoMi cells, which was the only cell line with increased GADD34 expression after exposure to XRT. The results obtained with YoMi cells were also the most suggestive of a synergistic effect. In KMBC and SKChA-1 cells, tumor volume reduction with combination therapy was reasonably good, but the overall effect was less pronounced and there was no suggestion of a synergistic interaction in either case; adding more virus did not change the nature of this interaction, although tumor volume reduction was greater. Indeed, the degree of synergy appeared to correlate with the postradiation levels of GADD34.
The results suggest that XRT augments viral replication to some extent, through a mechanism or mechanisms unrelated to GADD34, but that upregulation of GADD34 potentiates this even further and leads to treatment synergy. This possibility is supported by results from Advani et al. 11 showing that enhanced viral replication after XRT is not seen only in g 1 34.5-deficient strains. Furthermore, increased viral tumoricidal activity based on postradiation changes in expression of other genes has also been shown. Stanziale et al. 24 recently showed that XRT-mediated upregulation of ribonucleotide reductase (RR) augmented the tumoricidal activity of G207, an oncolytic HSV deficient in UL-39 (gene encoding the ICP6 protein that forms the large subunit of RR), as well as g 1 34.5. In this report, the enhanced viral activity was abrogated by treatment with hydroxyurea, a known inhibitor of RR. Clearly, XRT induces a number of changes in gene expression, any number or combination of which could impact on proliferation and tumoricidal activity of genetically modified HSV, and it is very likely that multiple mechanisms are involved. The impact of XRT on viral entry into tumor cells is also potentially important mechanistically and could also influence viral tumoricidal activity. 
Treatment of cholangiocarcinoma
The absence of increased GADD34 expression in two of the cells lines in the present study was an unexpected finding. The GADD family of proteins (GADD34, GADD45, GADD153) are induced by various stresses, such as radiation and chemotherapeutic agents, and their coordinate induction serves as a growth arrest signal in response to DNA damage. 25, 26 The principal function of these proteins is to stop cell cycle progression at the G1 and G2 checkpoints to allow for DNA repair. While induction of GADD45 is dependent on wild-type p53, this is not a requirement for induction of GADD34. 14, 27, 28 On the other hand, overexpression of the proto-oncogene c-Myc, which is common in many cancers, appears to be an important mediator of GADD expression. Amundson et al. 29 showed that overexpression of myc in Rat-1 fibroblasts nearly abolished induction of GADD34, GADD45 and GADD153 after exposure to an alkylating agent and ultraviolet irradiation. Whether or not c-Myc is overexpressed in KMBC and SK-ChA-1 cells used in the present study is unknown, but this is one possible explanation for the observed absence of GADD34 induction.
In summary, human cholangiocarcinoma can be effectively treated by oncolytic HSV, although sensitivity to virus varies among cell lines. XRT appears to promote replication of oncolytic HSV through a mechanism that does necessarily require upregulation of GADD34 in the target cell. However, for viral strains deficient in the g 1 34.5 gene such as NV1023, tumoricidal activity appears to be further enhanced by XRT-induced upregulation of GADD34, which restores this deletion in the viral genome and results in treatment synergy. This effect is cell type dependent, since viral tumoricidal activity is less favorably impacted in cell lines that do not upregulate GADD34 after XRT. It is likely that other postradiation molecular changes impact the viral lytic life cycle, and further investigation is required to fully delineate these interactions. Nevertheless, it is apparent that combined XRT and oncolytic viral therapy is a potent and potentially important treatment strategy that offers the possibility of enhancing the therapeutic ratios of both individual therapies.
